Timolol (tablet): Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 1: Line 1:
{{Timolol}}
{{DrugProjectFormSinglePage
{{Drugbox
|genericName=generic name
| verifiedrevid = 457286138
|aOrAn=a
| IUPAC_name = (''S'')-1-(''tert''-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
|drugClass=Adrenergic receptor agonist
| image = Timol01.jpg
|indication=a list of indications, separated by commas.
| image2 =Timolol02.png
|hasBlackBoxWarning=Yes
|adverseReactions=a list of adverse reactions, separated by commas.
|blackBoxWarningTitle=Warning Title
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult======Condition 1=====


<!--Clinical data-->
* Dosing Information
| tradename = Timoptic
 
| Drugs.com = {{drugs.com|monograph|timolol-eent}}
:* (Dosage)
| MedlinePlus = a602022
 
| pregnancy_AU = C
=====Condition 2=====
| pregnancy_US = C
 
| legal_status = Rx-only
* Dosing Information
| routes_of_administration = oral, [[human eye|Ophthalmic]]
 
:* (Dosage)
|offLabelAdultGuideSupport======Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelAdultNoGuideSupport======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
|fdaLIADPed======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
|offLabelPedGuideSupport======Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information/Recommendation
 
:* (Dosage)
|offLabelPedNoGuideSupport======Condition 1=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:* (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:* (Dosage)
|contraindications=* Condition 1
* Condition 2
* Condition 3
* Condition 4
* Condition 5
|warnings======Conidition 1=====
 
(Description)
 
|clinicalTrials=======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
=====Condition 2=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
|postmarketing=(Description)
|drugInteractions=* Drug 1
* Drug 2
* Drug 3
* Drug 4
* Drug 5
 
=====Drug 1=====
 
(Description)
 
=====Drug 2=====
 
(Description)
 
=====Drug 3=====
 
(Description)
 
=====Drug 4=====
 
(Description)
 
=====Drug 5=====
 
(Description)
|useInPregnancyFDA=(Description)
|useInPregnancyAUS=(Description)
|useInLaborDelivery=(Description)
|useInNursing=(Description)
|useInPed=(Description)
|useInGeri=(Description)
|useInGender=(Description)
|useInRace=(Description)
|useInRenalImpair=(Description)
|useInHepaticImpair=(Description)
|useInReproPotential=(Description)
|useInImmunocomp=(Description)
|othersTitle=Others
|useInOthers=(Description)
 
|administration=(Oral/Intravenous/etc)
|monitoring======Condition 1=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 2=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 3=====
 
(Description regarding monitoring, from ''Warnings'' section)
|IVCompat====Solution===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Y-Site===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Admixture===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Syringe===
 
====Compatible====


<!--Pharmacokinetic data-->
* Solution 1
| bioavailability = 60%
* Solution 2
| metabolism = [[Liver|Hepatic]]: 80%
* Solution 3
| elimination_half-life = 2.5-5 hours
| excretion = [[Kidney|Renal]]


<!--Identifiers-->
====Not Tested====
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 26839-75-8
| ATC_prefix = C07
| ATC_suffix = AA06
| ATC_supplemental = {{ATC|S01|ED01}}
| PubChem = 33624
| IUPHAR_ligand = 565
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00373
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 31013
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5JKY92S7BR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08600
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9599
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 499


<!--Chemical data-->
* Solution 1
| C=13 | H=24 | N=4 | O=3 | S=1  
* Solution 2
| molecular_weight = 316.421 g/mol
* Solution 3
| smiles = O[C@H](COc1nsnc1N2CCOCC2)CNC(C)(C)C
| InChI = 1/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
| InChIKey = BLJRIMJGRPQVNF-JTQLQIEIBV
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BLJRIMJGRPQVNF-JTQLQIEISA-N
}}
__NOTOC__
{{CMG}}


'''''For patient information about Timolol Tablet, click [[Timolol Oral (patient information)|here]].'''''
====Variable====


'''''For patient information about Timolol Drop/Solution, click [[Timolol Ophthalmic (patient information)|here]].'''''
* Solution 1
* Solution 2
* Solution 3


{{SB}} Betimol, Blocadren, Istalol, Timoptic, Timoptic-XE, Timoptic OcuDose
====Incompatible====


==Overview==
* Solution 1
* Solution 2
* Solution 3


'''Timolol maleate''' is a non-selective [[beta blocker|beta-adrenergic receptor antagonist]] indicated for treating [[glaucoma]], [[myocardial infarction|heart attacks]] and [[hypertension]].
===TPN/TNA===


==Category==
====Compatible====


Beta-blockers
* Solution 1
* Solution 2
* Solution 3


==FDA Package Insert==
====Not Tested====


====TIMOLOL MALEATE tablet====
* Solution 1
* Solution 2
* Solution 3


'''  [[Timolol tablet indications and usage|Indications and Usage]]'''
====Variable====
'''| [[Timolol tablet dosage and administration|Dosage and Administration]]'''
'''| [[Timolol tablet contraindications|Contraindications]]'''
'''| [[Timolol tablet warnings and precautions|Warnings and Precautions]]'''
'''| [[Timolol tablet adverse reactions|Adverse Reactions]]'''
'''| [[Timolol tablet drug interactions|Drug Interactions]]'''
'''| [[Timolol tablet use in specific populations|Use in Specific Populations]]'''
'''| [[Timolol tablet overdosage|Overdosage]]'''
'''| [[Timolol tablet description|Description]]'''
'''| [[Timolol tablet clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Timolol tablet how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[Timolol tablet labels and packages|Labels and Packages]]'''


{|
* Solution 1
| [[File:Ti01.png|800px|thumb]]
* Solution 2
|}
* Solution 3


==Uses==
====Incompatible====


In its oral form ('''Blocadren'''), it is used:
* Solution 1
* to treat [[hypertension|high blood pressure]]
* Solution 2
* to prevent [[myocardial infarction|heart attack]]s
* Solution 3
* to prevent [[migraine]] headaches<ref name="MarcusBain2009">{{cite book|author1=Dawn A. Marcus|author2=Philip A. Bain|title=Effective Migraine Treatment in Pregnant and Lactating Women: A Practical Guide|url=http://books.google.com/books?id=Z5YWpjj89NEC&pg=PA141|accessdate=14 November 2010|date=27 February 2009|publisher=シュプリンガー・ジャパン株式会社|isbn=978-1-60327-438-8|pages=141–}}</ref>
|overdose====Acute Overdose===


In its [[human eye|ophthalmic]] form (brand names '''Timoptol''' in Italy; '''Timoptic'''), it is used to treat open-angle and occasionally secondary [[glaucoma]] by reducing aqueous humour production through blockage of the beta receptors on the ciliary epithelium. The pharmacological mechanism by which it actually does this is still unknown.  First beta-blocker approved for topical use in treatment of glaucoma in the USA (1978).  With monotherapy, depresses [[Intraocular pressure|IOP]] 18-34% below baseline within first few treatments.  However, there are short-term escape and long-term drift effects in some patients.  That is, tolerance develops.  May reduce extent of diurnal IOP curve up to 50%.  IOP higher during sleep.  5-10x more potent beta-blocker than propranolol.  Light sensitive; preserved with 0.01% benzalkonium Cl (and also comes BAC free).  Can also be used in adjunctive therapy with pilocarpine or CAIs.
====Signs and Symptoms====


==Side effects==
(Description)


The most serious possible side effects include cardiac [[arrhythmia]]s and severe [[bronchospasm]]s. Timolol can also lead to [[Syncope (medicine)|fainting]], [[congestive heart failure]], [[clinical depression|depression]], [[confusion]], worsening of [[Raynaud's syndrome]] and [[impotence]].
====Management====


==Usual dosage==
(Description)


*Children and Adults: Ophthalmic: Initial: 0.25% solution, instill 1 drop twice daily; increase to 0.5% solution if response not adequate; decrease to 1 drop/day if *controlled; do not exceed 2 drops twice daily of 0.5% solution Adults: Oral:
===Chronic Overdose===
*Hypertension: Initial: 10&nbsp;mg twice daily, increase gradually every 14 days, usual dosage: 20–40&nbsp;mg/day in 2 divided doses; maximum: 60&nbsp;mg/day
*Prevention of myocardial infarction: 10&nbsp;mg twice daily initiated within 1–6 weeks after infarction
*Migraine headache: Initial: 10&nbsp;mg twice daily, increase to maximum of 30&nbsp;mg/day


==Formulations==
====Signs and Symptoms====


*Gel-forming solution, ophthalmic, as maleate (Timoptic-XE): 0.25% (2.5 mL, 5 mL); 0.5% (2.5 mL, 5 mL)
(Description)
*Solution, ophthalmic, as hemihydrate (Betimol): 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains [[benzalkonium chloride]]]
*Solution, ophthalmic, as maleate: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]
*Timoptic: 0.25% (5 mL, 10 mL); 0.5% (5 mL, 10 mL) [contains benzalkonium chloride]
*Solution, ophthalmic, as maleate [preservative free] (Timoptic OcuDose): 0.25% (0.2 mL);0.5% (0.2 mL) [single use]
*Tablet, as maleate (Blocadren): 5&nbsp;mg, 10&nbsp;mg, 20&nbsp;mg


For ophthalmic use, timolol is also available combined with other medications:
====Management====


*[[Combigan]] - timolol and [[brimonidine]]
(Description)
*IOTIM-B - timolol and brimonidine
|drugBox={{Drugbox2
*[[Cosopt]] - timolol maleate and [[Dorzolamide|dorzolamide hydrochloride]]
| verifiedrevid =
*[[Alcon#Glaucoma|DuoTrav]] - timolol and [[travoprost]]
| IUPAC_name =
*XOalacom (Pfizer) - timolol and latanoprost
| image =
| drug_name =


==Brand names==
<!--Clinical data-->
| tradename =  
| MedlinePlus =  
| licence_US =  
| pregnancy_AU =
| pregnancy_US =
| legal_status =
| routes_of_administration =


* In Canada: Apo-Timol, Apo-Timop, Gen-Timolol, Nu-Timolol, Phoxal-timolol, PMS-Timolol, Tim-AK, Timoptic, Timoptic-XE.
<!--Pharmacokinetic data-->
* In the United States: Betimol, Blocadren, Istalol, Timoptic, Timoptic-XE, Timoptic OcuDose.
| bioavailability =
* In Jordan: Apimol.
| metabolism =
* IOTIM is No. 1 prescribed brand in INDIA from FDC LIMITED.
| elimination_half-life =
| excretion =


==Chemical synthesis==
<!--Identifiers-->
| CAS_number_Ref =  
| CAS_number =  
| ATC_prefix =  
| ATC_suffix =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =  


{|
<!--Chemical data-->
| [[File:Timolol03.png|800px|thumb]]
| C= | H= | N= | O=
|}
| molecular_weight =
| smiles =
| InChI =
| InChIKey =
| StdInChI_Ref =
| StdInChI =
| StdInChIKey_Ref =
| StdInChIKey =
| melting_point =
}}
|mechAction=(Description)
|structure=(Description with picture)
|PD=(Description)
|PK=(Description)
|nonClinToxic=(Description)
|clinicalStudies======Condition 1=====


==Mechanism of Action==
(Description)


Timolol maleate is a beta1 and beta2 (nonselective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic activity.
=====Condition 2=====


==References==
(Description)
{{Reflist|2}}


{{Beta blockers}}
=====Condition 3=====
{{Antiglaucoma preparations and miotics}}


[[Category:Beta blockers]]
(Description)
[[Category:Morpholines]]
|howSupplied=(Description)
[[Category:Cardiovascular Drugs]]
|fdaPatientInfo=(Patient Counseling Information)
[[Category:Antimigraine drugs]]
|nlmPatientInfo=(Link to patient information page)
[[Category:Drugs]]
|lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
|drugShortage=Drug Shortage
}}

Revision as of 13:15, 14 July 2014

Timolol (tablet)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)

Overview

Timolol (tablet) is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
Conidition 1

(Description)

Adverse Reactions

Clinical Trials Experience

Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): (Description)
Pregnancy Category (AUS): (Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatic Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Females of Reproductive Potential and Males

(Description)

Immunocompromised Patients

(Description)

Others

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Timolol (tablet)
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

Storage

There is limited information regarding Timolol (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Timolol (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Timolol (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

(Patient Counseling Information)

Precautions with Alcohol

Alcohol-Timolol (tablet) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Timolol (tablet) Brand Names in the drug label.

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Timolol_(tablet)&oldid=993443"